Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2018-11-19 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Research Briefing Presentations 57 pages 3.4MB
Investor Presentation Classification · 95% confidence The document is a detailed investor research briefing presentation by Pharmaxis dated November 20, 2018. It contains extensive information about the company's drug discovery capabilities, pipeline, partnerships, clinical trials, and business strategy. The content includes forward-looking statements, scientific and clinical data, management team details, and program agendas. It is structured as a presentation with slides and speaker notes, focusing on financial position, product pipeline, and strategic partnerships. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a transcript of a call, nor a regulatory filing or announcement. The document is a detailed investor presentation aimed at providing financial, strategic, and scientific information to investors and stakeholders. Therefore, the most appropriate classification is Investor Presentation (IP).
2018-11-19 English
Pharmaxis Investor Research Briefing 2 pages 117.2KB
Investor Presentation Classification · 90% confidence The document is a media release dated 15 November 2018 announcing an upcoming investor research briefing event scheduled for 20 November. It describes the event's content, including presentations by senior research executives and an overview of the company's drug discovery pipeline. The document does not contain any financial statements, detailed financial data, or regulatory filings. It is an announcement of an investor presentation event rather than the presentation itself or a formal report. The document length is 3874 characters, which is relatively short and consistent with a media release or announcement. Therefore, the most appropriate classification is Investor Presentation (IP), as it relates to an event focused on investor information and company strategy, even though the actual presentation will occur later and is not included here. Confidence is high given the clear description of the event and absence of financial data or regulatory content.
2018-11-14 English
Pharmaxis Releases Positive Results of Phase 1 Clinical Tria 2 pages 121.5KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 15 November 2018 from Pharmaxis Ltd announcing positive results from a Phase 1 clinical trial for a drug compound. It discusses clinical trial stages, safety findings, pharmacokinetic profiles, and future plans for licensing agreements. There is no financial data, regulatory filing references, or detailed financial performance information. The content is a corporate announcement about clinical trial results rather than a financial report, regulatory filing, or management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press release about clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-11-14 English
Appendix 4C - quarterly 5 pages 127.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date, cash flow from operating, investing, and financing activities, estimated cash outflows for the next quarter, and compliance statements. The presence of quarterly financial data and the nature of the report align with a comprehensive interim or quarterly financial report. The document is 8580 characters long, which is sufficient to contain substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2018-10-25 English
Quarterly Shareholder Update - September 2018 9 pages 378.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – September 2018' and contains detailed information about the company's recent capital raise, drug development pipeline, clinical trial updates, sales figures for products, and corporate news including a board appointment. It is a comprehensive update for shareholders covering a quarter's activities and financial highlights. The presence of substantive financial data, operational updates, and strategic information for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. It is not merely an announcement or a brief factsheet, but a detailed quarterly report with financial and operational content. Therefore, the appropriate classification is 'Interim / Quarterly Report (IR)'. Q1 2019
2018-10-25 English
Notice of Annual General Meeting/Proxy Form 11 pages 463.6KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF THE 2018 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT OF PHARMAXIS LTD' and includes details about the date, time, and location of the AGM, proxy voting instructions, and descriptions of the business to be conducted at the meeting such as consideration of financial statements, remuneration report, re-election of a director, grant of securities, and renewal of takeover provisions. It also contains an explanatory statement about the items to be voted on. The document is a formal notice and explanatory statement sent to shareholders in advance of the AGM, not the actual AGM materials or minutes. It does not contain the full financial statements or detailed financial performance data but rather informs shareholders about the meeting and the resolutions to be considered. Therefore, this document fits the category of AGM Information (AGM-R).
2018-10-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.